3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs
Open Access
- 26 January 2017
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 2 (2) , e91377
Abstract
Idiopathic pulmonary fibrosis (IPF) is a fatal progressive fibrotic lung disease characterized by the presence of invasive myofibroblasts in the lung. Currently, there are only two FDA-approved drugs (pirfenidone and nintedanib) for the treatment of IPF. There are no defined criteria to guide specific drug therapy. New methodologies are needed not only to predict personalized drug therapy, but also to screen novel molecules that are on the horizon for treatment of IPF. We have developed a model system that exploits the invasive phenotype of IPF lung tissue. This ex vivo 3D model uses lung tissue from patients to develop pulmospheres. Pulmospheres are 3D spheroids composed of cells derived exclusively from primary lung biopsies and inclusive of lung cell types reflective of those in situ, in the patient. We tested the pulmospheres of 20 subjects with IPF and 9 control subjects to evaluate the responsiveness of individual patients to antifibrotic drugs. Clinical parameters and outcomes were also followed in the same patients. Our results suggest that pulmospheres simulate the microenvironment in the lung and serve as a personalized and predictive model for assessing responsiveness to antifibrotic drugs in patients with IPF.Keywords
This publication has 42 references indexed in Scilit:
- Multiplex Profiling of Cellular Invasion in 3D Cell Culture ModelsPLOS ONE, 2013
- FAK-Related Nonkinase Is a Multifunctional Negative Regulator of Pulmonary FibrosisThe American Journal of Pathology, 2013
- Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosisJournal of Clinical Investigation, 2013
- Myofibroblasts in interstitial lung diseases show diverse electron microscopic and invasive featuresLaboratory Investigation, 2012
- Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44Journal of Experimental Medicine, 2011
- New Insights into the Pathogenesis and Treatment of Idiopathic Pulmonary FibrosisDrugs, 2011
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- β-Arrestin Deficiency Protects Against Pulmonary Fibrosis in Mice and Prevents Fibroblast Invasion of Extracellular MatrixScience Translational Medicine, 2011
- Pirfenidone in idiopathic pulmonary fibrosisDrugs of Today, 2010
- Collagen-based cell migration models in vitro and in vivoSeminars in Cell & Developmental Biology, 2009